SCHEMBL6490439

SCHEMBL6490439

O=C(O)Cc1cc2cc(O)c(O)cc2oc1=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 5/20 0.54
MCL1 Q07820 2/20 0.54
GPR35 Q9HC97 4/20 0.45
PON1 P27169 1/20 0.44
KDM4E B2RXH2 3/20 0.43
HPGD P15428 3/20 0.43
GAA P10253 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
CA12 O43570 1/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
CYP1A2 P05177 1/20 0.43
BCHE P06276 1/20 0.43
GLA P06280 1/20 0.43
CYP3A4 P08684 1/20 0.43
MAPT P10636 1/20 0.43
ALOX15 P16050 1/20 0.43
ACHE P22303 1/20 0.43
PTGS1 P23219 1/20 0.43
CASP1 P29466 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2274941 0.81 POLB (0.57) AKR1B1MCL1KDM4EHPGDGAA
SCHEMBL30002655 0.81 POLB (0.57) AKR1B1MCL1KDM4EHPGDGAA
SCHEMBL2403666 0.77 RAB9A (0.59) AKR1B1GPR35KDM4EHPGDSMN1; SMN2
SCHEMBL11128154 0.76 NPC1 (0.55) SMN1; SMN2CA12ALDH1A1MAPTALOX15
SCHEMBL10626736 0.76 MAOB (0.61) SMN1; SMN2CA12MAPTALOX15ACHE
SCHEMBL2791740 0.76 AKR1B1 (0.61) AKR1B1MCL1GPR35PON1KDM4E
SCHEMBL10845026 0.75 CA12 (0.50) AKR1B1KDM4ECA12GLACA9
SCHEMBL4150207 0.74 CA12 (0.48) AKR1B1CA12CA9MEN1NPC1
SCHEMBL8809509 0.74 CA12 (0.35) AKR1B1MCL1KDM4EHPGDGAA
SCHEMBL29628919 0.74 GPR35 (0.76) GPR35KDM4ECA12ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951870-B2 Coumarin derivatives with COMT inhibiting activity ORION CORPORATION (FI) 2005-10-04 US disclosed
CN-1199963-C Coumarin derivatives with COMT inhibiting activity ORION CORP (FI) 2005-05-04 CN disclosed
US-20040110750-A9 Coumarin derivatives with comt inhibiting activity ORION CORPORATION (FI) 2004-06-10 US disclosed
EP-1301503-B1 COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY ORION CORP (FI) 2004-02-25 EP disclosed
US-20030186975-A1 Coumarin derivatives with comt inhibiting activity PYSTYNEN JARMO (FI) 2003-10-02 US disclosed
CN-1440399-A Coumarin derivatives with COMT inhibiting activity ORION CORP (FI) 2003-09-03 CN disclosed
EP-1301503-A1 COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY ORION CORPORATION (FI) 2003-04-16 EP disclosed
WO-2002002548-A1 COUMARIN DERIVATIVES WITH COMT INHIBITING ACTIVITY ORION CORPORATION (FI) 2002-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110750-A9 Coumarin derivatives with comt inhibiting activity COMT, CYP1A1, CYP2D6 AKR1B1 136/4885MCL1 3402/4885GPR35 2731/4885
US-20030186975-A1 Coumarin derivatives with comt inhibiting activity COMT, CYP1A1, CYP2D6 AKR1B1 136/4885MCL1 3402/4885GPR35 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.